title: Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma.
abstract: Elevated levels of cell-free DNA (cfDNA) are frequently observed in tumor patients. Activating mutations in exon 4 (R183) and exon 5 (Q209) of GNAQ and GNA 11 are almost exclusively found in uveal melanoma, thus providing a highly specific marker for the presence of circulating tumor DNA (ctDNA). To establish a reliable, noninvasive assay that might allow early detection and monitoring of metastatic disease, we determined the proportion of GNAQ or GNA 11 mutant reads in cfDNA of uveal melanoma patients by ultradeep sequencing. Cell-free DNA from 28 uveal melanoma patients with metastases or extraocular growth was isolated and quantified by real-time polymerase chain reaction (PCR) (7-1550 ng DNA/mL plasma). GNAQ and GNA 11 regions of interest were amplified in 22 of 28 patients and ultradeep sequencing of amplicons was performed to detect even low proportions of mutant reads. We detected Q209 mutations (2-38% mutant reads) in either GNAQ or GNA 11 in the plasma of 9 of 22 metastasized patients. No correlation between the proportion of mutant reads and the concentration of cfDNA could be detected. Among the nine ctDNA-positive patients, four had metastases in bone, whereas no metastases were detected in the 13 ctDNA-negative patients at this location (P = 0.025). Furthermore, ctDNA-positive patients tended to be younger at initial diagnosis and show larger metastases. The results show that ultradeep amplicon sequencing can be used to detect tumor DNA in plasma of metastasized uveal melanoma patients. It remains to be shown if this approach can be used for early detection of disseminated tumor disease.
authors: Department of Ophthalmology, Faculty of Medicine, University Duisburg-Essen Essen, Germany.
authors: Claudia Hd
authors: CH
authors: Metz
authors: Max
authors: M
authors: Scheulen
authors: Norbert
authors: N
authors: Bornfeld
authors: Dietmar
authors: D
authors: Lohmann
authors: Michael
authors: M
authors: Zeschnigk
mesh_terms: D000328:Adult; D000368:Aged; D001483:Base Sequence; D001859:Bone Neoplasms / Q000556:secondary; D004247:DNA / Q000097:blood* / Q000235:genetics*; D005260:Female; D044385:GTP-Binding Protein alpha Subunits / Q000235:genetics*; D043802:GTP-Binding Protein alpha Subunits, Gq-G11; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008545:Melanoma / Q000097:blood / Q000235:genetics*; D008875:Middle Aged; D017422:Sequence Analysis, DNA; D014604:Uveal Neoplasms / Q000097:blood / Q000235:genetics*; D000098943:Uveal Melanoma
chemical_list: C554062:GNA11 protein, human; C554061:GNAQ protein, human; D044385:GTP-Binding Protein alpha Subunits; D004247:DNA; D043802:GTP-Binding Protein alpha Subunits, Gq-G11
keywords: Biomarker; GNAQ; cell-free DNA; ultradeep sequencing; uveal melanoma
references: Clin Chim Acta. 2010 Nov 11;411(21-22):1611-24
references: 20688053
references: Cancer Res. 2001 Apr 15;61(8):3439-42
references: 11309305
references: Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16368-73
references: 16258065
references: N Engl J Med. 2010 Dec 2;363(23):2191-9
references: 21083380
references: Lancet. 1996 May 4;347(9010):1222-5
references: 8622452
references: Cancer Treat Rev. 2002 Oct;28(5):255-71
references: 12435372
references: Arch Ophthalmol. 2001 May;119(5):670-6
references: 11346394
references: Clin Chim Acta. 2008 Jan;387(1-2):55-8
references: 17916343
references: PLoS One. 2011;6(9):e23418
references: 21909401
references: Cancer Res. 2001 Feb 15;61(4):1659-65
references: 11245480
references: Nature. 2008 Nov 6;456(7218):53-9
references: 18987734
references: Br J Cancer. 2010 Jul 27;103(3):285-90
references: 20661247
references: Ann N Y Acad Sci. 2001 Sep;945:258-64
references: 11708488
references: Nat Med. 2008 Sep;14(9):985-90
references: 18670422
references: Cancer Metastasis Rev. 1999;18(1):65-73
references: 10505546
references: Ophthalmol Clin North Am. 2005 Mar;18(1):75-84, viii
references: 15763193
references: Clin Cancer Res. 2012 Jul 15;18(14):3934-41
references: 22645051
references: Nature. 2009 Jan 29;457(7229):599-602
references: 19078957
references: Am J Med Genet A. 2008 Jan 1;146A(1):78-82
references: 17975803
references: Br J Ophthalmol. 2011 May;95(5):620-3
references: 21378004
references: C R Seances Soc Biol Fil. 1948 Feb;142(3-4):241-3
references: 18875018
references: Nature. 2005 Sep 15;437(7057):376-80
references: 16056220
references: Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5230-4
references: 18719078
references: J Clin Oncol. 2004 Oct 15;22(20):4157-64
references: 15483026
references: Cases J. 2009 Nov 10;2:189
references: 19946499
references: Hugo J. 2010 Dec;4(1-4):11-21
references: 22132062
references: Cancer Res. 2012 Jul 15;72(14):3492-8
references: 22581825
references: Am J Ophthalmol. 2004 Feb;137(2):236-43
references: 14962411
references: Cancer Genet Cytogenet. 2000 Oct 1;122(1):13-7
references: 11104026
references: Br J Cancer. 2009 Sep 1;101(5):813-5
references: 19654573